Influence of local anaesthetics on inflammatory activity postburn.
Most studies investigating the pathophysiological processes taking place inside an experimental burn wound use in vitro techniques, which only allow for fragmented measurements of the actual and complex processes occurring inside a burn wound in vivo. In the present study, which used a recently developed in vivo technique in the rat, a full-thickness burn was induced and resulted in the formation of a subcutaneous gelatinous edema with distinct borders to the surrounding connective tissue and free communication with the systemic circulation allowing it to be easily separated for further analysis. In the present study, we investigated the effects of topical local anaesthetics (EMLA) on the inflammatory cascade of a burn wound in vivo. Results showed significantly higher myeloperoxidase (MPO) levels in EMLA-treated burned animals (P<0.01) versus placebo-treated burned controls. EMLA treatment induced a significant inhibition of the synthesis of leukotrien B(4) (LTB(4)) (P<0.001), prostaglandin E(1) (PGE(1)) (P<0.001), prostaglandin E(2) (PGE(2)) (P<0.001) and thromboxane B(2) (TXB(2)) (P<0.001) versus control, while free radical formation did not differ significantly between EMLA-treated and control animals. In conclusion, topical local anaesthetics significantly inhibit the release of several mediators known to take important part in the pathophysiological events ensuing a burn injury, such as activation of pain mechanisms (PGE), oedema formation (LTB), and postburn ischemia (TXB). The increased numbers of leukocytes (MPO) in the burn wound induced by topical local anaesthetic treatment could suggest increased influx and/or increased viability of leukocytes postburn.
Yregård
Liselotte
L
Department of Anesthesiology, Institution of Surgical Specialties, Sahlgrenska University Hospital, S-43180 Mölndal, Sweden.
Cassuto
Jean
J
Tarnow
Peter
P
Nilsson
Ulf
U
D000287:Administration, Topical; D000779:Anesthetics, Local / Q000008:administration & dosage*; D000818:Animals; D002056:Burns / Q000188:drug therapy* / Q000378:metabolism* / Q000503:physiopathology; D005609:Free Radicals / Q000378:metabolism; D007249:Inflammation / Q000378:metabolism / Q000503:physiopathology; D007975:Leukotriene B4 / Q000378:metabolism; D008012:Lidocaine / Q000008:administration & dosage*; D000077442:Lidocaine, Prilocaine Drug Combination; D008297:Male; D023421:Models, Animal; D009195:Peroxidase / Q000378:metabolism; D011318:Prilocaine / Q000008:administration & dosage*; D011458:Prostaglandins E / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D013929:Thromboxane B2 / Q000378:metabolism
D000779:Anesthetics, Local; D005609:Free Radicals; D000077442:Lidocaine, Prilocaine Drug Combination; D011458:Prostaglandins E; D011318:Prilocaine; D007975:Leukotriene B4; D013929:Thromboxane B2; D008012:Lidocaine; D009195:Peroxidase